Though the expression of M2 macrophage-specific antigen CD163 varied significantly in primary breast cancer, its prevalence has a prognostic impact on both relapse-free survival and overall survival (Figure S1), which could be explained by fusion between macrophages and cancer cells [44]. This evidence concerns the gene CD163 and breast carcinoma.